Toxicology letters
Cadmium interferes with the antiproliferative effect of fulvestrant in endocrine therapy-resistant estrogen receptor α-positive breast cancer cells.
Koki Kanameda, Masayo Hirao-Suzuki, Shuso Takeda
Published: 202610.1016/j.toxlet.2026.111829
Abstract
Fulvestrant (FUL), an estrogen receptor α (ERα)-degradative anti-estrogen, is used alone or in combination with cyclin-dependent kinase 4/6 inhibitors for the treatment of advanced ERα-positive breast cancer (BC) in postmenopausal women. Cadmium (Cd)…
Preview only. Read the full abstract at the source